2008: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's: Therapeutics
Search or Browse by Day

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's: Therapeutics

Monday, October 27, 2008
1220
MQX-503, a Novel Topical Nitroglycerin Formulation, Improves Severity of Symptoms Associated with Raynaud’s Phenomenon
1221
Treatment With Imatinib Does Not Only Prevent Fibrosis In Different Models Of Ssc, But Also Induces Regression Of Established Fibrosis
1222
Phase IIa Trial of Imatinib Mesylate (Gleevec) in the Treatment of Diffuse Systemic Sclerosis - An Interim Analysis
1223
Autologous Stem Cell Transplantation for Severe Systemic Sclerosis: Update on the ASTIS-trial
1224
Systemic Sclerosis and Lung Transplantation: A Single Center Experience
1225
Long-term Effects of Bosentan Treatment on Survival in Patients with Pulmonary Arterial Hypertension Related to Connective Tissue Disease: TRUST 3-year data
See more of: ACR Abstract Submission ACR Concurrent Abstract Session
<< Previous Session Level | Next Session Level >>